Healthcare practice, both in the UK and internationally is in a state of flux. Change is arising both from economic stringencies and new opportunities, underpinned by emerging scientific and technologically driven developments. Arguably, some of the most significant developments involve the recent rapid advances in medical imaging. The technological pull is most acute in the management of chronic disease, where the current population-based treatment strategies ignore many of the opportunities for personalization of care. These opportunities could be seized through early diagnosis and more effective treatments for the individual patient.
Advances in imaging are revolutionizing the way to treat diseases, whether it be accurately locating the position of a tumour or providing a method that allows early diagnosis of a disease. In the clinic, around 45 million magnetic resonance imaging (MRI) scans are taken every year, of which 40% use a contrast agent to enhance signal intensity selectively. Radioisotope tracers are equally widely used, e.g. for blood perfusion imaging using positron emission tomography (PET, e.g. 18 F-labelled probes such as fluorodeoxyglucose (FDG) or 68 Ga-labelled peptides and proteins) or gamma-imaging (SPECT, e.g. with 99m Tc, 111 In). However, the basic approach in such studies has not changed through the course of this period, and most imaging studies rely on relatively simple functional imaging of tissue or the blood pool. of cheaper instrumentation, though it is becoming clear that significant practical obstacles restrict the application of such dual-modal techniques, beyond well-established single modality applications such as those involving, for example, 18 F-FDG.
The field of molecular imaging already encompasses a number of areas in which intense research activity is in progress. Of these, radioisotope tomography (PET/SPECT), magnetic resonance methods (MRI/MRS/PARACEST/PARASHIFT) and optical (OI) or multispectral optoacoustic methods (MSOT) are the most prominent. Despite the similar goals and related challenges facing the researchers involved, there is limited overlap between these diverse areas. Furthermore, the effectiveness of translation from the laboratory to the clinic needs to improve dramatically. For instance, many of the current approaches to targeted and responsive systems can work only in model systems, because the importance of localization, sensitivity and quantification is often neglected.
Since the emergence of molecular imaging over 20 years ago, it has become one of the most rapidly growing fields of scientific research, spanning multiple disciplines such as medicine, chemistry, pharmacology, physics, cell biology and biomedical engineering. The development of new approaches to imaging is defined by overlap of all these areas but chemistry is firmly at its core. This meeting brought together key players involved in the development of a wide variety of imaging modalities, particularly PET/SPECT tomography, MRI/MRS, optical imaging and optoacoustic imaging.
If we are to realize the true potential of molecular imaging, and deliver a series of breakthroughs, it is imperative that the communities mentioned above communicate with each other to identify common goals and key issues that influence the outcome of their research. At the most fundamental level, there is a need to educate researchers to devise kinetically stable probe systems that should not possess any acute/chronic toxicity problems, or give rise to unwanted off-target accumulation/irradiation effects. Furthermore, there is a need to define what is feasible, in terms of targets, detection limits and time scales.
There is tremendous potential for innovation in medical imaging to have high impact, particularly with the increased number and cost of individual therapies, which are often not particularly effective. The economically inefficient 'one size fits all' approach persists, at a time when healthcare is under severe financial pressure and so there is a timely opportunity for novel imaging approaches to deliver on this vision of stratified medicine. Progress in medical imaging research is underpinned by parallel developments in complementary disciplines, including biomedicine, biology, chemistry, engineering, physics and computer science. Advancing research at the intersection of these fields represents one of the most promising strategies to develop imaging technologies that will have major clinical impact.
This collection of articles follows two Royal Society Discussion Meetings held in March 2017 at Carlton House Terrace and Chicheley Hall. These meetings served to showcase the current status of the field, and provided a forum to discuss the chemical challenges facing further development. The conviviality of the Chicheley venue, in particular, promoted some particularly stimulating sessions. Thus, the articles presented here address many different aspects of contemporary chemistry, relating to the future of imaging. As well as containing primary papers and reviews of developments in each of the key imaging modalities, there is considerable reflection about the future. Anderson & Lewis [1] muse on the prospects for imaging biomarkers and targeted therapies, while Mulder and co-workers [2] , Archibald [3] and Hyeon and co-workers [4] explore the challenges of nano-materials in imaging. Sherry and co-workers [5] and Louie and co-workers [6] define future prospects for advanced magnetic resonance methods. A very thoughtful article from Tzoumas & Ntziachristos [7] also assesses the future role that multispectral optical methods can play where image analysis methods are critically important. Of particular relevance to optical imaging development, Kikuchi [8] reports on new strategies that allow control of the optical signal in the near-IR spectral region. We were also fortunate to have an incisive industrial perspective from Murphy et al. [9] , which identifies needs and niches that must be explored collectively.
Some general points emerge from these discussions. In particular, translation continues to present a considerable challenge to the community, meaning that better mechanisms need to be developed to facilitate effective communication between primary researchers and end users. Furthermore, while early diagnosis is the key to effective (and cost effective) treatment of disease, there are limiting financial models that restrict the use and development of diagnostics. These limitations are compounded by the need to use intellectual resources effectively, across a range of areas. We hope that these meetings and articles constitute the beginning of the next phase of a broader dialogue, in which academics and industry can work together more effectively to address these important challenges in the chemistry of molecular imaging.
